Haya Therapeutics

News

Pathos AI's big $365m Series D, and other bio financings

Our round-up of recent biotech financings includes rounds for Pathos AI, Stylus Medicine, Haya Therapeutics, Therini Bio and Tiltbio.

News

Samir Ounzain, CEO and co-founder of Haya Therapeutics

Lilly to hunt non-coding DNA for obesity drugs in $1bn deal

Swiss start-up Haya Therapeutics has formed a partnership with Eli Lilly – worth up to $1 billion – to look for new therapies for obesity in non-coding DNA.

News

Manufacturing issues mar ITM's radiopharma filing, says FDA

ITM's first attempt to score FDA approval for one of its radiopharma therapies has been knocked back by the agency.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks